Diuretics are color blind

JAMA

Volumn 293, Issue 13, 2005, Pages 1663-1666

  Neaton, James D ^a   Kuller, Lewis H ^b  

^a UNIVERSITY OF MINNESOTA   (United States)

^b UNIVERSITY OF PITTSBURGH GRADUATE SCHOOL OF PUBLIC HEALTH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACEBUTOLOL; ALPHA ADRENERGIC RECEPTOR BLOCKING AGENT; AMLODIPINE; ANGIOTENSIN RECEPTOR ANTAGONIST; ANTIHYPERTENSIVE AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; CHLORTALIDONE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; DOXAZOSIN; ENALAPRIL; LISINOPRIL; QUINAPRIL; SULFONAMIDE;

BLOOD PRESSURE REGULATION; CLINICAL FEATURE; CLINICAL TRIAL; DIETARY INTAKE; EDITORIAL; EPIDEMIOLOGICAL DATA; HUMAN; HYPERCHOLESTEROLEMIA; HYPERGLYCEMIA; HYPERTENSION; HYPERTRIGLYCERIDEMIA; HYPOKALEMIA; ISCHEMIC HEART DISEASE; NEGRO; PRIORITY JOURNAL; STROKE; TREATMENT INDICATION; TREATMENT OUTCOME; ETHNOLOGY; NOTE;

AFRICAN CONTINENTAL ANCESTRY GROUP; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; ANTIHYPERTENSIVE AGENTS; CALCIUM CHANNEL BLOCKERS; DIURETICS; HUMANS; HYPERTENSION; SULFONAMIDES;

EID: 15944392286     PISSN: 00987484     EISSN: None     Source Type: Journal    
DOI: 10.1001/jama.293.13.1663     Document Type: Editorial

References (36)

1. MacMahon SW, Cutler JA, Furberg CD, et al. The effects of drug treatment for hypertension on morbidity and mortality from cardiovascular disease: a review of randomized controlled trials. Prog Cardiovasc Dis. 1986;29(suppl 1):99-119.
2. Davis BR, Cutler JA, Gordon DG, et al. Rationale and design for the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). Am J Hypertens. 1996;9:342-360.
3. American Heart Association; American Stroke Association. Heart disease and stroke statistics-2005 update. Available at: http://www.americanheart.org. Accessed March 11, 2005.
4. ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group. Major cardiovascular events in hypertensive patients randomized to doxazosin vs chlorthalidone: the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). JAMA. 2000;283:1967-1975.
5. ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group. Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). JAMA. 2002;288:2981-2997.
6. Wright JT, Dunn JK, Cutler JA, et al. Outcomes in hypertensive black and non-black patients treated with chlorthalidone, amlodipine, and lisinopril. JAMA. 2005;293:1595-1608.
7. Davey-Smith G, Neaton JD, Wentworth DN, Stamler R, Stamler J; MRFIT Research Group. Mortality differences between black and white men in the USA: contribution of income and other risk factors among men screened for MRFIT. Lancet. 1998;351:934-939.
8. Klag MJ, Whelton PK, Randall BL, Neaton JD, Brancati FL, Stamler J. End stage renal disease in African-American and white men: 16-year MRFIT findings. JAMA. 1997;277:1293-1298.
9. Hypertension Detection and Follow-up Program Cooperative Group. Five-year findings of the hypertension detection and follow-up program, I: reduction in mortality of persons with high blood pressure, including mild hypertension. JAMA. 1979;242:2562-2571.
10. Hypertension Detection and Follow-up Program Cooperative Group. Five-year findings of the hypertension detection and follow-up program, II: mortality by race-sex and age. JAMA. 1979;242:2572-2577.
11. Hypertension Detection and Follow-up Program Cooperative Group. Persistence of reduction in blood pressure and mortality of participants in the Hypertension Detection and Follow-up Program. JAMA. 1988;259:2113-2122.
12. Neaton JD, Grimm RH, Prineas RJ, et al. Treatment of Mild Hypertension Study: final results. JAMA. 1993;270:713-724.
13. SHEP Cooperative Research Group. Prevention of stroke by antihypertensive drug treatment in older persons with isolated systolic hypertension: final results of the Systolic Hypertension in the Elderly Program (SGEP). JAMA. 1991;265:3255-3264.
14. Collins R, Peto R, MacMahon S, et al. Blood pressure, stroke, and coronary heart disease, part 2: short-term reductions in blood pressure: overview of randomized drug trials in their epidemiologic context. Lancet. 1990;335:827-838.
15. Dahlof B, Lindholm LH, Hansson L, et al. Morbidity and mortality in the Swedish Trial in Old Patients with Hypertension (STOP-Hypertension). Lancet. 1991;338:1281-1285.
16. Blood Pressure Lowering Treatment Trialists' Collaboration. Effects of different blood-pressure-lowering regimens on major cardiovascular events: results of prospectively-designed overviews of randomized trials. Lancet. 2003;362:1527-1535.
17. Neaton JD, Kuller L, Stamler J, Wentworth DN. Impact of systolic and diastolic blood pressure on cardiovascular mortality. In: Laragh J, Brennen BM, eds. Hypertension: Pathophysiology, Diagnosis, and Management. New York, NY: Raven Press; 1995.
18. Prospective Studies Collaboration. Age-specific relevance of usual blood pressure to vascular mortality: a meta-analysis of individual data for one million adults in 61 prospective studies. Lancet. 2002;360:1903-1913.
19. Levy D, Larson MC, Vasan RS, Kannel WB, Ho KKL. The progression from hypertension to congestive heart failure. JAMA. 1996;275:1557-1562.
20. Grimm RH Jr, Margolis K, Papademetriou V, et al. Baseline characteristics of participants in the Antihypertensive and Lipid Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). Hypertension. 2001;37:19-27.
21. Hajjar IM, Grim CE, George V, Kotchen TA. Impact of diet on blood pressure and age-related changes in blood pressure in the US population: analysis of NHANES III. Arch Intern Med. 2001;161:589-593.
22. Intersalt Cooperative Research Group. Intersalt: an international study of electrolyte excretion and blood pressure: results for 24-hour urinary sodium and potassium excretion. BMJ. 1988;297:319-328.
23. Vollmer WM, Sacks FM, Ard J, et al. Effects of diet and sodium intake on blood pressure: subgroup analysis of the DASH-Sodium Trial. Ann Intern Med. 2001;135:1019-1028.
24. Morris RC Jr, Sebastian A, Forman A, Tanaka M, Schmidlin O. Normotensive salt sensitivity: effects of race and dietary potassium. Hypertension. 1999;33:18-23.
25. Aviv A, Hollenberg NK, Weder A. Urinary potassium excretion and sodium sensitivity in blacks. Hypertension. 2004;43:707-713.
26. Bagrov AY, Lakatta EG. The dietary sodium-blood pressure plot "stiffens." Hypertension. 2004;44:22-24.
27. Gates PE, Tanaka H, Hiatt WR, Seals DR. Dietary sodium restriction rapidly improves large elastic artery compliance in older adults with systolic hypertension. Hypertension. 2004;44:35-41.
28. Tishkoff SA, Williams SM. Genetic analysis of African populations: human evolution and complex disease. Nat Rev Genet. 2002;3:611-621.
29. Sankar P, Cho MK. Toward a new vocabulary of human genetic variation. Science. 2002;298:1337-1338.
30. Schelleman H, Stricker BHC, de Boer A, et al. Drug-gene interactions between genetic polymorphisms and antihypertensive therapy. Drugs. 2004;64:1801-1816.
31. Duster T. Race and reification in science. Science. 2005;307:1050-1051.
32. Mokwe E, Ohmit SE, Nasser SA, et al. Determinants of blood pressure response to quinapril in black and white hypertensive patients: the Quinapril Titration Interval Management Evaluation trial. Hypertension. 2004;43:1202-1207.
33. Sorlie P, Rogot E, Anderson R, et al. Black-white mortality differences by family income. Lancet. 1992;340:346-350.
34. Dyer AR, Liu K, Walsh M, et al. Ten-year incidence of elevated blood pressure and its predictors: The Cardia Study. J Hum Hypertens. 1999;13:13-20.
35. Chobanian AV, Bakris GL, Black HR, et al. The seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. JAMA. 2003;289:2560-2572.
36. Appel LJ, Moore TJ, Obarzanek E, et al. A clinical trial of dietary patterns on blood pressure. N Engl J Med. 1997;336:1117-1124.